CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
| Autor: | Gang Cheng, WuQiang Fan, Yin Wu, Seyed Abbas Mirabbasi, Bahar Khalighi, Stanley R. Walker, Archana Kodali, Koroush Khalighi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
lcsh:Internal medicine
medicine.medical_specialty Prasugrel CYP2C19 Disease 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Genotype Genetic variation Internal Medicine Medicine 030212 general & internal medicine Medical prescription lcsh:RC31-1245 Research Articles clopidogrel business.industry Clopidogrel Anesthesia pharmacogenetic business Pharmacogenetics Research Article medicine.drug |
| Zdroj: | Journal of Community Hospital Internal Medicine Perspectives Journal of Community Hospital Internal Medicine Perspectives, Vol 7, Iss 3, Pp 151-156 (2017) |
| ISSN: | 2000-9666 |
| Popis: | Background: Clopidogrel (Plavix) is an antiplatelet medication that is routinely used in patients with cardiovascular disease. Cytochrome P2C19 enzymes play a major role in its metabolism, which determines its varied therapeutic level and its effectiveness. Objectives: To customize clopidogrel therapy and evaluate its efficacy by using CYP2C19 genotypic and phenotypic information to improve clinical outcomes in patients. Methods: A total of 465 patients with underlying cardiovascular disease were selected from our out-patient cardiology clinic. DNA sequences of CYP2C19 were analyzed in 465 patients. Results: Of 465 patients, 183 were wild-type homozygous (*1/*1) and 18.8% gain-of function and 19.8% loss-of-function alleles in our patient population The following changes were made: 1) Switching to prasugrel in patients whose genotype noted them to be “Slow metabolizers. This medication adjustment improved clinical outcomes in this patient group. 2) Discontinuing or lowering clopidogrel doses in patients whose genotypes noted them to be “Fast or ultra-fast metabolizes” to decrease bleeding risk. For those who were not on clopidogrel but carried abnormal allele(s), “clopidogrel caution” was documented. These individuals were followed up for 3 years and there has not been any cardiac clinical symptoms, cardiac death or excessive bleeding reported. Conclusions: Given the varied effectiveness of clopidogrel due to its metabolism by CYP2C19 enzyme, and the relatively high frequency of both gain-of-function (18.8%) and loss-of-function (19.8%) alleles in our patient population, we believe that genotyping CYP2C19 is clinically important in order to improve patient outcomes and minimize patient risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |